Cidofovir, bearing the CAS number 113852-37-2, is a highly effective synthetic antiviral agent that plays a crucial role in treating serious viral infections. Its primary indication is the management of Cytomegalovirus (CMV) retinitis, a sight-threatening condition that frequently affects individuals with compromised immune systems, such as those suffering from HIV/AIDS. As a nucleoside analogue, Cidofovir exerts its antiviral effect by interfering with viral DNA replication. After cellular uptake and phosphorylation to its active diphosphate form, it competitively inhibits viral DNA polymerase. This action prevents the virus from synthesizing new genetic material and replicating, thereby controlling the infection.

The ability of Cidofovir to tackle CMV infections that are refractory to other treatments makes it an indispensable therapeutic option for many patients. Furthermore, the compound's antiviral properties are being explored for broader applications, including in dermatology. Topical applications of Cidofovir have shown promise in treating a range of viral skin conditions, such as common warts, anogenital warts, and molluscum contagiosum. These investigations suggest that Cidofovir may offer a versatile solution for various viral etiologies. For organizations and researchers seeking to procure Cidofovir, identifying reputable manufacturers and suppliers is a critical step. Sourcing high-quality Cidofovir from trusted chemical companies, particularly those in China with established manufacturing expertise, ensures product integrity and efficacy. Understanding the competitive price landscape and the reliability of suppliers is essential for making informed purchasing decisions for this vital pharmaceutical intermediate.